Standout Papers

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer 2017 2026 2020 2023 710
  1. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer (2017)
    Koji Haratani, Hidetoshi Hayashi et al. JAMA Oncology
  2. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial (2017)
    Toshiaki Takahashi, Takeharu Yamanaka et al. The Lancet Oncology

Immediate Impact

3 by Nobel laureates 13 from Science/Nature 58 standout
Sub-graph 1 of 23

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
3 intermediate papers

Works of Hiroyasu Kaneda being referenced

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
2017
Epidermal growth factor receptor lacking C‐terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor
2009

Author Peers

Author Last Decade Papers Cites
Hiroyasu Kaneda 2267 1587 1094 116 3.4k
Kathryn A. Gold 2092 1794 896 99 3.4k
Joshua K. Sabari 2084 1319 957 82 2.9k
Biagio Ricciuti 2475 1588 992 155 3.6k
Ticiana Leal 2410 1452 737 97 3.1k
Francisco Robert 1762 1352 1100 106 3.1k
Rita Chiari 2582 2288 1372 139 4.1k
Rafael Santana-Dávila 1617 1108 1640 69 3.5k
Fei Zhou 1847 1681 854 119 3.1k
Sandra J. Strauss 1230 1404 802 91 2.9k
Giulio Metro 2110 1788 1001 168 3.2k

All Works

Loading papers...

Rankless by CCL
2026